Literature DB >> 28139284

French Jardé's law and European regulation on drug trials: Harmonization and implementation of new rules.

Dominique Deplanque1, Sophie Sénéchal-Cohen2, François Lemaire3.   

Abstract

Jardé's law, concerning research studies in humans, was enacted in March 2012 but did not come into force until November 2016. This delay is largely explained by the adoption of a European regulation on clinical trials on medicinal products that will probably not be applicable until October 2018. In addition to covering the respective areas of the French and European legislation, the round table provided an opportunity to discuss the principal measures that will apply to future research, particularly those concerning the operational procedures of the ethics committees and the national committee for research in humans, as well as measures relating to the management of serious adverse effects, more specifically in phase I studies in subjects not presenting with any disorder. This round table also enabled the formulation of recommendations to better anticipate the practical difficulties that the regulatory changes might engender. Finally, we highlight the numerous challenges in terms of training that these important regulatory changes impose and the absolute necessity to best adapt the restrictions to those that are planned in numerous other European countries so that France remains competitive in terms of clinical research and so that French patients may continue to benefit rapidly from the most innovative treatments.
Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adverse effects; Clinical research; Ethics committee; European regulation; Jardé’s law; Phase I; Regulation; Training

Mesh:

Year:  2017        PMID: 28139284     DOI: 10.1016/j.therap.2016.12.006

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  5 in total

1.  Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients.

Authors:  Mehran Monchi; Thomas Bruneau; Sebastien Jochmans; David Veyer; Aurelia Pitsch; Olivier Ellrodt; Marie Picque; Valérie Taly; Oumar Sy; Sandie Mazerand; Sylvain Diamantis; Hélène Péré
Journal:  iScience       Date:  2022-03-14

2.  COVID-19 among nursing home residents: results of an urgent pre-hospital intervention by a multidisciplinary task force.

Authors:  François Dolveck; Alessio Strazzulla; Coralie Noel; Sylvie Aufaure; Paul Tarteret; Astrid de Pontfarcy; Nicolas Briole; Nicolas Vignier; Sylvain Diamantis
Journal:  Braz J Infect Dis       Date:  2020-12-05       Impact factor: 1.949

3.  Risk of Multidrug Resistant Bacteria Acquisition in Patients with Declared β-Lactam Allergy during Hospitalization in Intensive Care Unit: A Retrospective Cohort Study (2007-2018).

Authors:  Alessio Strazzulla; Maria Concetta Postorino; Nabil Belfeki; Laura Iordache; Astrid de Pontfarcy; Aurelia Pitsch; Pierre Leroy; Sebastien Jochmans; Mehran Monchi; Sylvain Diamantis
Journal:  J Immunol Res       Date:  2022-01-12       Impact factor: 4.818

4.  Trimethoprim-sulfamethoxazole as de-escalation in ventilator-associated pneumonia: a cohort study subanalysis.

Authors:  Alessio Strazzulla; Maria Concetta Postorino; Tracie Youbong; Maxence Rouyer; Clara Flateau; Catherine Chakvetadze; Astrid de Pontfarcy; Aurelia Pitsch; Sebastien Jochmans; Nabil Belfeki; Mehran Monchi; Sylvain Diamantis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-24       Impact factor: 3.267

5.  The Predictive Value of Cell Blood Count Parameters to Diagnose Pulmonary Embolism in Patients with SARS-CoV-2 Infection: A Case Control Study.

Authors:  Alessio Strazzulla; Sarra Abroug Ben Halima; Ibrahim Chouchane; Marwa Rezek; Marcella Pinto Stiebler; Sarra Hamrouni; Mohammad Maalaoui; Nouha Ghriss; Renaud Guedec-Ghelfi; Cyrus Moini; Mehran Monchi; Nabil Belfeki
Journal:  Antibiotics (Basel)       Date:  2022-01-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.